跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-12
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

8月29日週六

合作

19:06
CNBC

OpenAI to end model access to Cursor after acquisition by Elon Musk's SpaceX

OpenAI will end Cursor's access to its models after Elon Musk's SpaceX acquired the coding-tool company.

文章預覽

Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points OpenAI plans to wind down its contract supplying models to Cursor, with a proposed Nov. 12 cutoff. OpenAI says it cannot be confident SpaceX will comply with its terms, citing past disputes with Elon Musk’s companies. CEO Michael Truell says OpenAI models account for about 5% of Cursor user traffic and that the companies are discussing the decision. In this article SPCX Follow your favorite stocks CREATE FREE ACCOUNT A combination photo shows CEO of OpenAI Sam Altman…

OpenAISpace Exploration Technologies Corp. (SpaceX) 開啟原文 ↗

產品

06:39
WDEZ

Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough

A feature on the Moderna and Merck cancer vaccine breakthrough, framed as success after a century of failed attempts at cancer vaccines.

文章預覽

By Michael Erman and Julie Steenhuysen Aug 28 (Reuters) – Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on August 13 when he got the call. An mRNA cancer vaccine the company had been developing with Merck had hit its mark — the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts. Cancer experts hailed it as the beginning of an era of custom-made vaccines that train the immune system to fight an individual patient’s cancer. In a ​trial of more than 1,000 patients with localized mela…

Moderna 開啟原文 ↗

監管

05:00
CNBC

Meta's $18 billion settlement puts TikTok and YouTube on notice. Who's next on the firing line?

Meta Platforms has reached an $18 billion settlement over teen-safety claims, which CNBC reports raises legal pressure on other social platforms. The $18 billion figure is the only one stated in the supplied item text.

文章預覽

Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Key Points Meta's $18 billion settlement in the social media addiction trial has shifted focus to other platforms. Under the settlement conditions, Meta called on YouTube and TikTok to also make changes to their apps. California's Attorney General Rob Bonta told CNBC he has plans to target other big players next. In this article META GOOGL SNAP Follow your favorite stocks CREATE FREE ACCOUNT Meta CEO Mark Zuckerberg leaves the federal courthouse in downtown Los Angeles…

Meta Platforms 開啟原文 ↗

人事

04:23
Yahoo Finance

General Electric (GE) Names Claire McDonough As GE Vernova CFO

Claire McDonough was named chief financial officer of GE Vernova.

文章預覽

General Electric (GE) Names Claire McDonough As GE Vernova CFO Bailey Pemberton Sat, August 29, 2026 at 2:23 PM GMT+10 3 min read GE GEV RIVN General Electric (NYSE:GE) energy unit GE Vernova appoints Rivian CFO Claire McDonough as its new Chief Financial Officer. McDonough is set to leave electric vehicle maker Rivian to take up the CFO role at GE Vernova. The move marks a key leadership change for GE's recently separated energy focused business. Executive moves like this often reflect how large industrial groups are thinking about growth, capital allocation and technology. It can be useful t…

GE Vernova 開啟原文 ↗

8月28日週五

產品

17:40
USA Today

Eli Lilly's diabetes drug Mounjaro gets approval for a new use

The FDA cleared Eli Lilly's Mounjaro for a new use tied to lowering heart attack risk, expanding the label on its diabetes franchise.

文章預覽

HEALTHCARE U.S. Food and Drug Administration Add Topic Eli Lilly's diabetes drug Mounjaro gets approval for a new use Ken Alltucker USA TODAY Aug. 28, 2026, 1:40 p.m. ET Hear this story The Food and Drug Administration approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes. The approval gives consumers another option when seeking a GLP-1 medication to lower heart-related health risk. In 2024, the FDA approved Novo Nordisk's anti-obesity drug, Wegovy, to lower the risk of cardiovascular events such as heart attack and…

Eli Lilly and Company 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天